HomeClinical TopicsFDA approves treatment for hepatitis C in children

FDA approves treatment for hepatitis C in children

Author(s):

On April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17.

Read more at fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content